Compare Amphastar Pharmaceuticals Inc (AMPH) vs iShares Gold Trust (IAU) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

IAU is trading at $77.26, down 0.32% with bearish technical signals dominating the short-term outlook. The stock shows mixed momentum with RSI indicators suggesting potential overbought conditions on shorter timeframes while longer-term indicators remain neutral. Recent market sentiment reflects uncertainty around gold prices, with central bank buying providing support but macroeconomic factors creating headwinds.

The stock faces near-term pressure from technical bearish signals and gold market volatility, though institutional accumulation during price weakness suggests long-term confidence. Key risks include Federal Reserve policy decisions and inflation data, while potential upside exists if geopolitical tensions or economic uncertainty drive safe-haven demand for gold-related assets.